Open Access. Powered by Scholars. Published by Universities.®
Articles 1 - 3 of 3
Full-Text Articles in Entire DC Network
The Calcitonin Assay And Multiple Endocrine Neoplasia Type 2 Syndromes: Historical Footnote, Kenneth E. W. Melvin
The Calcitonin Assay And Multiple Endocrine Neoplasia Type 2 Syndromes: Historical Footnote, Kenneth E. W. Melvin
Henry Ford Hospital Medical Journal
No abstract provided.
Multiple Endocrine Neoplasia Type 2 Syndromes In Japan, Shin-Ichiro Takai, Akira Miyauchi, Hideo Matsumoto, Tatsuro Ikeuchi, Tetsuro Miki, Kanji Kuma, Yuichi Kumahara
Multiple Endocrine Neoplasia Type 2 Syndromes In Japan, Shin-Ichiro Takai, Akira Miyauchi, Hideo Matsumoto, Tatsuro Ikeuchi, Tetsuro Miki, Kanji Kuma, Yuichi Kumahara
Henry Ford Hospital Medical Journal
Through nationwide surveys, we collected and analyzed 242 patients of medullary thyroid carcinoma (MTC). Included were 40 patients with multiple endocrine neoplasia type 2A (MEN-2A), six patients with MEN-2B, and 36 patients with only MTC having a positive family history (82 total patients in the hereditary group). Ten-year survival rates were 81.5% for all cases, and 97.5% and 76.1% for the hereditary and the sporadic group, respectively. Epinephrine/norepinephrine ratio in the urine was found to be a good indicator of the adrenomedullary hyperfunction in patients with hereditary MTC. At least one patient in each family with hereditary MTC had overt …
Prospects For The Medical Use Of Interferon In 1984, Bosko Postic, Julio C. Arroyo
Prospects For The Medical Use Of Interferon In 1984, Bosko Postic, Julio C. Arroyo
Henry Ford Hospital Medical Journal
Interferon, a natural and wide spectrum antiviral polypeptide that was discovered in 1957, has been extensively described. In addition to its antiviral effect, interferon has been found to suppress tumor growth and modulate the immune response. Until 1980, interferon was primarily prepared for clinical trials in human leukocytes derived from the buffy coat of whole blood. A major breakthrough occurred in the late 1970s when human interferon was produced by DNA recombinant methods in such heterologous cells as bacteria (genetic engineering). Interferon is not commercially available in 1984, but it may, based on clinical trials in humans, become part of …